These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457 [TBL] [Abstract][Full Text] [Related]
5. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event]. Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. De Stefano V; Teofili L; Leone G; Michiels JJ Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199 [TBL] [Abstract][Full Text] [Related]
7. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231 [No Abstract] [Full Text] [Related]
8. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis. Foucar CE; Stein BL JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872 [No Abstract] [Full Text] [Related]
9. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555 [TBL] [Abstract][Full Text] [Related]
10. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report]. Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study. Fan J; Wang Q; Luo B; Chen H; Wang Z; Niu J; Yuan J; Yuan X; Bai W; He C; Guo W; Li K; Yin Z; Fan D; Han G J Gastroenterol Hepatol; 2020 Jul; 35(7):1215-1222. PubMed ID: 31711259 [TBL] [Abstract][Full Text] [Related]
12. Budd-Chiari syndrome and portal vein thrombosis due to essential thrombocytosis. Coban S; Ertugrul I; Ekiz F; Akif Teber M; Yuksel O Platelets; 2010; 21(2):144-6. PubMed ID: 20085436 [TBL] [Abstract][Full Text] [Related]
13. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792 [TBL] [Abstract][Full Text] [Related]
14. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Brière JB Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275 [TBL] [Abstract][Full Text] [Related]
15. JAK2 mutations across a spectrum of venous thrombosis cases. Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270 [TBL] [Abstract][Full Text] [Related]
16. JAK2V617F mutation in patients with splanchnic vein thrombosis. Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956 [TBL] [Abstract][Full Text] [Related]
17. Multiple thrombophilic factors in a patient with Budd-Chiari syndrome. Brancaccio V; Iannaccone L; Margaglione M; Guardascione MA; Amitrano L Clin Lab Haematol; 2002 Feb; 24(1):61-3. PubMed ID: 11843901 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908 [TBL] [Abstract][Full Text] [Related]
19. [JAK2 mutation and thrombosis - recommendations for screening]. Linnemann B; Lindhoff-Last E Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574 [No Abstract] [Full Text] [Related]
20. JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis. Khan AA; Kumar V; Anand I; Kumar M; Sharma P; Bhargava M Hematol Oncol Stem Cell Ther; 2012; 5(1):66-8. PubMed ID: 22446615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]